Intercept Pharmaceuticals buy melinda
Start price
30.11.18
/
50%
€103.55
Target price
22.01.19
€108.24
Performance (%)
-2.77%
End price
22.01.19
€100.68
Summary
This prediction ended on 22.01.19 with a price of €100.68. With a performance of -2.77%, the BUY prediction for Intercept Pharmaceuticals by melinda closed slightly in the red. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intercept Pharmaceuticals | - | - | - | - |
| iShares Core DAX® | 4.094% | 3.543% | 17.404% | 20.326% |
| iShares Nasdaq 100 | 1.424% | 0.512% | 39.212% | 55.365% |
| iShares Nikkei 225® | -1.572% | -4.633% | 15.731% | 2.146% |
| iShares S&P 500 | 1.822% | 0.963% | 30.396% | 45.950% |
Comments by melinda for this prediction
In the thread Intercept Pharmaceuticals diskutieren
Soins de santé | Biotechnologie | Etats-Unis
Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases.
Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.
The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases.
Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.
The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Nombre d'employés : 507 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Intercept Pharmaceuticals
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€104.05
03.04.19
03.04.19
€112.75
04.11.21
04.11.21
-79.94%
04.01.21
04.01.21
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€57.01
08.03.18
08.03.18
€63.14
05.04.18
05.04.18
13.13%
05.04.18
05.04.18
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€49.29
12.02.18
12.02.18
€60.43
20.02.18
20.02.18
14.93%
20.02.18
20.02.18
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€51.64
28.09.17
28.09.17
€90.20
03.10.17
03.10.17
15.83%
03.10.17
03.10.17
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€114.84
13.03.17
13.03.17
€121.77
28.07.17
28.07.17
6.13%
28.07.17
28.07.17
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€146.12
07.04.16
07.04.16
€171.38
07.10.16
07.10.16
-5.24%
07.10.16
07.10.16
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€25.00
19.06.13
19.06.13
€27.00
19.12.13
19.12.13
65.99%
19.12.13
19.12.13